European Pharmaceutical Review
OCTOBER 6, 2023
Positive interim results from Moderna’s Phase I/II trial of mRNA-1083 , an investigational vaccine designed to immunise against both influenza and COVID-19, have been released. There are several benefits of the combination vaccine as a preventative measure against these respiratory conditions, according to the pharmaceutical company.
pharmaphorum
MARCH 12, 2021
If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufactured have confirmed just how dynamic the industry can be. And those volumes will only increase.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JULY 1, 2021
More recently, the rapid development of Moderna’s COVID-19 vaccine, which used many of the principles of synthetic biology, is yet more proof that this is an area on the cusp of the pharmaceutical R&D mainstream. About the interviewee.
pharmaphorum
OCTOBER 12, 2022
Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. As technology has evolved, biotech and pharmaceutical companies have increasingly leaned on AI to support drug development – including to make sense of the vast amounts of healthcare data available to them.
pharmaphorum
OCTOBER 18, 2021
The development of COVID-19 vaccines required levels of cooperation and pioneering science comparable to the Apollo space programme. Within 12 months of the outbreak, vaccines were being deployed to prevent severe infections, hospitalisation, and death. billion people have been fully vaccinated. And there are many.
PharmaShots
MAY 23, 2023
Propelled by constant innovatory winds, the Cell and Gene therapy market is anticipated to grow by 20 percent year-over-year through 2025. The company received its first approval from the Japanese government in 2019 to treat critical limb ischemia. With a total revenue of $52B, Merck & Co.
pharmaphorum
JANUARY 6, 2022
IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.
Expert insights. Personalized for you.
92 
Let's personalize your content